Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)

Journal of the American College of Cardiology

Volumn 32, Issue 6, 1998, Pages 1648-1656

  Ruotolo, Giacomo ^a   Ericsson, Carl Göran ^b   Tettamanti, Cristina ^a   Karpe, Fredrik ^a   Grip, Lars ^a   Svane, Bertil ^a   Nilsson, Jan ^a   De Faire, Ulf ^a   Hamsten, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BEZAFIBRATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DYSLIPOPROTEINEMIA; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS; BEZAFIBRATE; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; TREATMENT OUTCOME;

EID: 0032533219     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00442-2     Document Type: Article

References (36)

1. Watts G, Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996;7:341-55.
2. Brown G, Albers J, Fisher L, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
3. Barth J. Lipoproteins and the progression/regression of atherosclerosis. Baillieres Clin Endocrinol Metab 1995;9:849-66.
4. Blankenhorn D, Azen S, Kramsch D, et al. for the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76.
5. Hodis H, Mack W, Azen S, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.
6. Mack W, Krauss R, Hodis H. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vase Biol 1996;16: 697-704.
7. Watts G, Mandalia S, Brunt J, Slavin B, Coltart D, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461-7.
8. Alaupovic P, Mack W, Knight-Gibson C, Hodis H. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vase Biol 1997;17:715-22.
9. Hazzard W, Goldstein J, Schrott M, Motulsky A, Bierman E. Hyperlipidemia in coronary heart disease: 3. evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction. J Clin Invest 1973;52:1569-77.
10. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.
11. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
12. Jukema J, Bruschke A, van Boven A, et al. for the REGRESS Study Group. Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
13. de Faire U, Ericsson C-G, Hamsten A, Nilsson J for the BECAIT Investigators. Design features of a five-year bezafibrate coronary atherosclerosis intervention trial. Drugs Exp Clin Res 1995;21:105-24.
14. Carlson K. Lipoprotein fractionation. J Clin Pathol 1973;5 Suppl 26:32-7.
15. Zlatkis A, Zak B, Boyle AJ. New method for direct determination of serum cholesterol. J Lab Clin Med 1953;41:486-92.
16. Fletcher M. A colorimetric method for estimating serum triglycerides. Clin Chim Acta 1968;22:393-7.
17. Carlson LA. Determination of serum triglycerides. J Atheroscler Res 1963;3:334-6.
18. 3, without contamination of Lp(a), in human plasma. Clin Chim Acta 1981;113:123-34.
19. Dahlén G, Guyton J, Attar M, Farmer J, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74: 758-65.
20. Holmquist L. Quantification of human serum very low density apolipoproteins C-I, C-II, C-III and E by enzyme immunoassay. J Immunol Methods 1980;34:243-51.
21. Boquist S, Ruotolo G, Hellenius M-L, Danell-Toverud K, Karpe F, Hamsten A. Effects of a cardioselective β-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk. Atherosclerosis 1998;137:391-400.
22. Nichols AW, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol 1986;128:417-31.
23. Reiber J, van der Zwet P, von Land C, et al. Quantitative coronary angiography equipment and technical requirements. In: Reiber J, Serruys PW, editors. Advances in Quantitative Coronary Arteriography. Dordrecht: Kluwer Academic, 1993:75-111.
24. Austen W, Edwards J, Frye R, et al. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975;51 Suppl:5-40.
25. Levy R, Brensike J, Epstein S, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984;69:325-37.
26. Blankenhorn D, Nessim S, Johnson R, Sanmarco M, Azen S, CashinHemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-40.
27. Brown B, Zhao X, Sacco D, Albers J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
28. Pitt B, Mancini G, Ellis S, Rosman H, Park J, McGovern M. Pravastatin limitation of atherosclerosis in the coronary arteries (PLACI): reduction in atherosclerosis progression and clinical events. PLACI investigation. J Am Coll Cardiol 1995;26:1133-9.
29. Arntzenius A, Barth J. High density lipoproteins and regression of atherosclerosis. Neth J Cardiol 1991;4:41-5.
30. Ericsson C-G, Nilsson J, Grip L, Svane B, Hamsten A. Effect of bezafibrate treatment over 5 years on coronary plaques causing 20-50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997;80:1125-9.
31. Homma Y, Ozawa H, Kobayashi T, et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltranferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994;106:191-201.
32. Austin M, Edwards K. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996;7:167-71.
33. Krauss RM, Williams P, Brensike J, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987;2:62-6.
34. Sniderman A, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb Vase Biol 1993;13:629-36.
35. Schonfeld G. The effect of fibrates on lipoprotein and homeostatic coronary risk factors. Atherosclerosis 1994;111:161-74.
36. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.